n,n-dimethylarginine has been researched along with liraglutide in 1 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (liraglutide) | Trials (liraglutide) | Recent Studies (post-2010) (liraglutide) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 2,404 | 481 | 2,154 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | liraglutide (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B | 1 |
1 trial(s) available for n,n-dimethylarginine and liraglutide
| Article | Year |
|---|---|
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Microcirculation; Middle Aged; Plasminogen Activator Inhibitor 1; Proinsulin; Prospective Studies | 2012 |